Tagged with Data

USA Manuel Guzman, President of CAS, a division of the American Chemical Society, outlines the organization’s vital role in scientific knowledge management and its commitment to accelerating breakthroughs in biomedical research. In this interview, Guzman delves into CAS’s strategic partnership with Cleveland Clinic, the impact of AI and quantum computing in…

USA Regeneron has agreed to pay USD 256 million to acquire at-home DNA test maker 23andMe after the troubled firm declared bankruptcy. Through the buyout, Regeneron will acquire the data of 23andMe’s customers, obtaining the valuable genetic profiles of millions to potentially develop new and lucrative therapies. With ambiguous legal guidelines…

Saudi Arabia Mohamed Al Holibi, Regional Business Lead for Health Information Systems at Solventum, shares insights into the evolving role of healthcare data and digital transformation in Saudi Arabia. In this interview, he discusses Solventum’s commitment to supporting Vision 2030 through advanced AI-driven technologies, the implementation of Diagnosis-Related Groups (DRG) systems, and…

Switzerland Anne Mette Wiis Vogelsang, CVP & General Manager of Novo Nordisk Switzerland, discusses Switzerland’s progressive healthcare landscape while addressing key issues like diabetes care, obesity, and systemic healthcare challenges. Vogelsang also calls for increased prioritization of a holistic approach to health, highlighting the importance of primary and secondary prevention, early…

Global Some of the key projections for the global use of medicines up to 2028, drawn from IQVIA’s report, The Global Use of Medicines 2024: Outlook to 2028. The report states that growth outlook has been raised by 2 percentage points despite lower expectations for COVID-19 vaccines and therapeutics. This increase in…

Saudi Arabia Dr Mahmoud Alyamani, Health & Well-Being Sector Head at NEOM, the sustainable region taking shape in northwest Saudi Arabia. He discusses NEOM’s innovative healthcare vision, emphasizing a proactive, data-driven approach using digital twins and AI. He also highlights the importance of global partnerships to co-create advanced health solutions and NEOM’s…

China Writing in the July 2024 edition of DIA’s Global Forum magazine Mingcan DU and Fengyun (Vicky) HAN of Johnson & Johnson Global Regulatory Policy and Intelligence look back at the evolution of the use of real-world evidence (RWE) in regulatory decision-making in China, including key use cases and future prospects.…

Global Oskar Möbert, vice president of Veeva OpenData, discusses how standardizing customer reference data and systems organization-wide can help biopharmas scale globally and become more agile in their business.   Data quality can make or break an interaction with a healthcare professional (HCP). Reps with access to accurate customer data deliver treatment…

MEA Peter Lane lays out IQVIA’s nuanced and ambitious vision for healthcare in the vast AMESA region, focused on empowering smarter healthcare and improving patient outcomes. Lane explains how IQVIA hopes to do this through clinical research, maximizing data value, providing technology and analytics to healthcare systems, and ensuring global health…

Belgium Belgium, one of Europe’s most important countries for biopharmaceutical production and R&D, assumed presidency of the Council of the European Union on the first of January. As part of its Presidency Programme, Belgium has highlighted health as one of its 14 focus areas, with the hope of strengthening the three…

Portugal Mario Martins lays out IQVIA Portugal’s holistic approach to the healthcare sector, covering clinical trials, therapeutic studies, and technology solutions such as compliance CRM and quality control for manufacturing plants. He also foregrounds the importance of both local adaptation and global collaboration in capitalising on the unique challenges and opportunities…

Japan Toshi Tominaga of Keio University Hospital, writing in the January 2023 edition of the DIA Global Forum magazine, outlines some recent updates to Japanese drug registration legislation, including how domestically generated academic clinical data can be utilised.   Japan’s current regulatory framework for investigator-initiated trials (IITs) of drug candidates seems…